Therapeutic Antibodies: Bench to Market

Webinar Series of the Chinese Antibody Society

Upcoming Webinar

We don't have any active meetings as of now. New meetings will show up here as registration opens. Check back soon!

Recent Webinars

Sign in to view recordings

Computational Pipeline for Common Light Chain Engineering Enables Scalable Bispecific Antibody Development

09/20/2025

Dr. Per Greisen

Light chain mispairing represents a fundamental manufacturing challenge in bispecific antibody development, requiring complex protein engineering solutions or specialized expression systems. We developed an integrated computational platform that systematically engineers common light chains capable of pairing with multiple heavy chains while preserving antigen binding affinity and specificity. Our computational pipeline …

Delivering Light and Heat Radiolabeled Antibodies for Cancer Diagnosis and Therapy

08/30/2025

Dr. Anna M. Wu

Radiolabeling antibodies with gamma- or positron-emitting radionuclides for imaging, or alpha- or beta-emitters for therapeutic radionuclide delivery, provides molecularly targeted approaches for diagnosis and therapy.  Protein engineering has been used to optimize many characteristics of tumor-specific antibodies for immunoPET and radioimmunotherapy, particularly through PK-optimized engineered antibody fragments. Preclinical and clinical …

Developing Delivery Devices for Biologics and Vaccines

04/26/2025

Dr. Jiaying Shen

The development of biologics and vaccines increasingly relies on effective delivery devices, making combination products a critical focus in both innovation and regulatory compliance. This seminar will provide an overview of combination product and regulatory landscape in US and EU, introduce typical delivery devices for biologics and vaccines and the …

Development of next-generation T cell-based cancer immunotherapy

02/08/2025

Prof. Peng Wu

The development of adoptive cell transfer and immune checkpoint inhibitor-based therapies has revolutionized cancer treatment. However, more than 50% of cancer patients fail to respond to these therapies. In this talk, I will discuss our recent progress in the development of FucoID as a new approach to identify antigen-specific T …

Icon